3.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Precedente Chiudi:
$3.36
Aprire:
$3.335
Volume 24 ore:
568.28K
Relative Volume:
0.24
Capitalizzazione di mercato:
$289.65M
Reddito:
$32.31M
Utile/perdita netta:
$-237.09M
Rapporto P/E:
-1.2014
EPS:
-2.88
Flusso di cassa netto:
$-219.11M
1 W Prestazione:
+21.83%
1M Prestazione:
+64.76%
6M Prestazione:
+145.39%
1 anno Prestazione:
-38.32%
Editas Medicine Inc Stock (EDIT) Company Profile
Nome
Editas Medicine Inc
Settore
Industria
Telefono
617-401-9000
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Confronta EDIT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
EDIT
Editas Medicine Inc
|
3.46 | 281.28M | 32.31M | -237.09M | -219.11M | -2.88 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-28 | Iniziato | H.C. Wainwright | Buy |
2024-12-16 | Downgrade | JP Morgan | Neutral → Underweight |
2024-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
2024-12-13 | Downgrade | Stifel | Buy → Hold |
2024-12-13 | Downgrade | Truist | Buy → Hold |
2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2024-11-25 | Downgrade | BofA Securities | Buy → Underperform |
2024-11-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
2024-11-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
2024-08-08 | Aggiornamento | BofA Securities | Neutral → Buy |
2024-05-09 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2023-10-24 | Aggiornamento | Citigroup | Neutral → Buy |
2023-10-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2023-09-29 | Aggiornamento | Stifel | Hold → Buy |
2023-06-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
2022-12-13 | Iniziato | Citigroup | Neutral |
2022-12-06 | Ripresa | Credit Suisse | Neutral |
2022-11-18 | Downgrade | Credit Suisse | Outperform → Neutral |
2022-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
2022-09-29 | Iniziato | BofA Securities | Neutral |
2021-10-19 | Iniziato | SVB Leerink | Mkt Perform |
2021-09-24 | Iniziato | Stifel | Hold |
2021-09-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
2021-08-09 | Aggiornamento | Truist | Hold → Buy |
2021-08-05 | Aggiornamento | Evercore ISI | Underperform → Outperform |
2021-06-04 | Ripresa | Robert W. Baird | Outperform |
2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
2021-04-16 | Iniziato | Goldman | Sell |
2021-03-22 | Iniziato | Credit Suisse | Outperform |
2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
2021-02-26 | Downgrade | Truist | Buy → Hold |
2021-01-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2021-01-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
2020-12-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2020-11-03 | Iniziato | Robert W. Baird | Underperform |
2020-06-18 | Ripresa | SunTrust | Buy |
2020-02-21 | Iniziato | Wells Fargo | Equal Weight |
2019-04-12 | Iniziato | Evercore ISI | Outperform |
2018-10-10 | Iniziato | Guggenheim | Neutral |
2018-09-21 | Iniziato | Raymond James | Outperform |
2018-05-15 | Reiterato | Chardan Capital Markets | Buy |
2018-02-13 | Iniziato | CLSA | Underperform |
2018-01-23 | Aggiornamento | SunTrust | Hold → Buy |
2017-07-14 | Iniziato | SunTrust | Hold |
2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
2016-08-10 | Aggiornamento | Jefferies | Hold → Buy |
2016-06-02 | Iniziato | Jefferies | Hold |
2016-02-29 | Iniziato | JMP Securities | Mkt Outperform |
2016-02-29 | Iniziato | JP Morgan | Neutral |
2016-02-29 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Editas Medicine Inc Borsa (EDIT) Ultime notizie
What analysts say about Editas Medicine Inc. stockBreakout stock performance - Autocar Professional
Is Editas Medicine Inc. a good long term investmentExceptional profit margins - Autocar Professional
Editas Medicine Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com
There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump - simplywall.st
What drives Editas Medicine Inc. stock priceConsistent high-yield stocks - Autocar Professional
What makes Editas Medicine Inc. stock price move sharplyVerified Return Tips - beatles.ru
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Numerous Editas Medicine Insiders Sold Stock: Not A Positive Omen - simplywall.st
Crispr Genomic Cure Market in 2032: A Glimpse Into the Future - openPR.com
Editas Medicine (EDIT) Soars 7.69% on Positive Data - AInvest
Cathie Wood shells out $13.9 million for one high-stakes biotech stock - Yahoo Finance
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data - MSN
Restore Health – Therapies that cureTelethon - Ricerca Malattie Genetiche Rare
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 3000E Index - MarketScreener
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? - The Motley Fool
2 Beaten-Down Stocks to Avoid - The Globe and Mail
Gene Editing Market Set to Witness Significant Growth by 2025-2032 | CRISPR Therapeutics, Editas Medicine - openPR.com
Gene editing stocks gain amid FDA's latest leadership change (EDIT:NASDAQ) - Seeking Alpha
Cancer Gene Therapy Market Set to Soar: Breakthrough - openPR.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - AOL.com
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Position Trimmed by Bank of America Corp DE - MarketBeat
Analysts Offer Predictions for Editas Medicine FY2026 Earnings - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine (EDIT) Unveils Promising Gene Editing Data for B - GuruFocus
Kalkine: Editas Medicine’s In Vivo Gene Editing Progress Unveiled at EHA 2025 with tLNP Approach - Kalkine Media
Breakthrough: New Gene Editing Therapy Achieves 58% Success Rate for Sickle Cell Disease Treatment - Stock Titan
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle - GuruFocus
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema - GuruFocus
Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method - Nasdaq
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - The Manila Times
Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Yahoo Finance
Editas Medicine Inc Azioni (EDIT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):